CATANESE, SILVIA
 Distribuzione geografica
Continente #
NA - Nord America 588
EU - Europa 293
AS - Asia 124
AF - Africa 53
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.059
Nazione #
US - Stati Uniti d'America 578
IT - Italia 109
SE - Svezia 84
SG - Singapore 57
CI - Costa d'Avorio 37
BG - Bulgaria 36
CN - Cina 31
GB - Regno Unito 21
AT - Austria 13
DE - Germania 11
FR - Francia 11
NG - Nigeria 11
VN - Vietnam 10
CA - Canada 8
IN - India 8
JP - Giappone 8
SN - Senegal 5
HK - Hong Kong 4
PL - Polonia 3
CR - Costa Rica 2
KR - Corea 2
CZ - Repubblica Ceca 1
ES - Italia 1
EU - Europa 1
FI - Finlandia 1
ID - Indonesia 1
IR - Iran 1
LK - Sri Lanka 1
NL - Olanda 1
PK - Pakistan 1
UA - Ucraina 1
Totale 1.059
Città #
Chandler 82
Fairfield 75
Abidjan 37
Seattle 37
Sofia 36
Woodbridge 34
New York 32
Ann Arbor 30
Cambridge 28
Ashburn 26
Houston 24
Wilmington 23
Florence 21
Boardman 19
Singapore 18
Beijing 17
Milan 17
Lawrence 14
Pisa 14
Princeton 14
Vienna 13
London 12
Lagos 11
Medford 10
Boulder 8
Des Moines 8
Ogden 8
Serra 8
Kent 6
San Diego 6
Dakar 5
Hyderabad 5
Los Angeles 5
Ottawa 5
Dong Ket 4
Frankfurt am Main 4
Hong Kong 4
Piombino 4
Bremen 3
Lancaster 3
Nanjing 3
Vicopisano 3
Ansbach 2
Changsha 2
Dearborn 2
Hefei 2
Lucca 2
Norwalk 2
Philadelphia 2
Romainville 2
San José 2
Sesto San Giovanni 2
Warsaw 2
Calgary 1
Casaleone 1
Cesano Boscone 1
Chiswick 1
Dallas 1
Formigine 1
Fulham 1
Garbagnate Milanese 1
Hebei 1
Islington 1
Jakarta 1
Jiaxing 1
Jinan 1
Leiden 1
Livorno 1
Madison 1
Massa 1
Minerbio 1
Minneapolis 1
Nanchang 1
New Delhi 1
North Bay 1
Olomouc 1
Paris 1
Pietrasanta 1
Prineville 1
Redwood City 1
Rome 1
Rosignano Marittimo 1
Santa Clara 1
Sapporo 1
Seongnam-si 1
Shanghai 1
Southwark 1
Springfield 1
Stuttgart 1
Tianjin 1
Torrevieja 1
Vicenza 1
Yokohama 1
Totale 798
Nome #
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors 112
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 112
Lights and shadows of molecular pathology and immunotherapy in adjuvant setting of patients with pancreatic ductal adenocarcinoma: Tumor volume and microsatellite instability inversely affect early progression free survival 93
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 92
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 79
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. 78
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 70
MICROSATELLITE INSTABILITY AND TUMOR VOLUME INVERSELY AFFECT EARLY PROGRESSION FREE SURVIVAL IN ADJUVANT SETTING OF PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA: LIGHTS AND SHADOWS OF MOLECULAR PATHOLOGY AND IMMUNOTHERAPY 66
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 63
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 61
TUMOR VOLUME AND MICROSATELLITE INSTABILITY INVERSELY AFFECT EARLY PROGRESSION FREE SURVIVAL IN ADJUVANT SETTING OF PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA: LIGHTS AND SHADOWS OF MOLECULAR PATHOLOGY AND IMMUNOTHERAPY 47
THE ROLE OF MOLECULAR PATHOLOGY AND IMMUNOTHERAPY IN ADJUVANT SETTING OF PANCREATIC DUCTAL ADENOCARCINOMA: TUMOR VOLUME AND MICROSATELLITE INSTABILITY INVERSELY AFFECT EARLY PROGRESSION FREE SURVIVAL 46
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 45
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 42
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients 39
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action 14
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer 12
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 6
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 5
Totale 1.082
Categoria #
all - tutte 4.536
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.536


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020114 0 0 0 12 12 15 15 14 12 9 21 4
2020/2021116 5 4 6 5 6 25 4 5 16 12 10 18
2021/2022146 0 4 1 4 35 22 3 2 10 11 7 47
2022/2023323 32 55 21 12 41 31 1 29 64 0 31 6
2023/2024178 11 14 26 11 14 36 15 2 5 3 19 22
2024/202552 4 25 22 1 0 0 0 0 0 0 0 0
Totale 1.082